Fluidigm Corporation (NASDAQ: FLDM) and Allscripts Healthcare Solutions (NASDAQ:MDRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitabiliy, dividends, analyst recommendations and institutional ownership.
Risk & Volatility
Fluidigm Corporation has a beta of 3.45, suggesting that its stock price is 245% more volatile than the S&P 500. Comparatively, Allscripts Healthcare Solutions has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Valuation & Earnings
This table compares Fluidigm Corporation and Allscripts Healthcare Solutions’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Fluidigm Corporation | $100.98 million | 0.93 | -$64.73 million | ($2.46) | -1.30 |
| Allscripts Healthcare Solutions | $1.62 billion | 1.38 | $153.38 million | ($1.06) | -11.66 |
Allscripts Healthcare Solutions has higher revenue and earnings than Fluidigm Corporation. Allscripts Healthcare Solutions is trading at a lower price-to-earnings ratio than Fluidigm Corporation, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Fluidigm Corporation and Allscripts Healthcare Solutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fluidigm Corporation | -74.05% | -104.38% | -18.13% |
| Allscripts Healthcare Solutions | -11.54% | 5.97% | 1.96% |
Insider & Institutional Ownership
91.7% of Fluidigm Corporation shares are owned by institutional investors. 4.7% of Fluidigm Corporation shares are owned by company insiders. Comparatively, 0.8% of Allscripts Healthcare Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Fluidigm Corporation and Allscripts Healthcare Solutions, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fluidigm Corporation | 0 | 0 | 1 | 0 | 3.00 |
| Allscripts Healthcare Solutions | 1 | 8 | 8 | 0 | 2.41 |
Fluidigm Corporation presently has a consensus price target of $9.00, suggesting a potential upside of 182.13%. Allscripts Healthcare Solutions has a consensus price target of $14.50, suggesting a potential upside of 17.31%. Given Fluidigm Corporation’s stronger consensus rating and higher probable upside, research analysts clearly believe Fluidigm Corporation is more favorable than Allscripts Healthcare Solutions.
Summary
Allscripts Healthcare Solutions beats Fluidigm Corporation on 8 of the 13 factors compared between the two stocks.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
